⌘K

Home/Filings/4/0001213900-23-004886

4//SEC Filing

WILSON GLYNN 4

Accession 0001213900-23-004886

CIK 0001937993other

View on SEC.gov Company Profile

Filed

Jan 23, 7:00 PM ET

Accepted

Jan 24, 5:02 PM ET

Size

6.9 KB

Accession

0001213900-23-004886

Insider Transaction Report

Form 4

Period: 2023-01-24

Cadrenal Therapeutics, Inc.CVKD

Director

Transactions

Conversion
Common Stock
2023-01-24+50,000→ 50,000 total
Conversion
Convertible Promissory Note
2023-01-24−50,000→ 0 total
Exercise: $1.00→ Common Stock (50,000 underlying)

Footnotes (1)

[F1]Upon consummation of the initial public offering of Cadrenal Therapeutics, Inc. on January 24, 2023, Dr. Wilson was issued 50,000 shares of common stock pursuant to the conversion of a convertible promissory note in the principal amount of $50,000, based on a conversion price of $1.00 per share.

Documents

1 file

4
ownership.xmlPrimary

Issuer

Cadrenal Therapeutics, Inc.

CIK 0001937993

Entity typeother

Related Parties

1

filerCIK 0001405625

Filing Metadata

Form type: 4
Filed: Jan 23, 7:00 PM ET
Accepted: Jan 24, 5:02 PM ET
Size: 6.9 KB

View on SEC.gov